Skip to main content
ClinicalTrials.govrestricted

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects

ClinicalTrials.gov study NCT00570258. IPD Sharing: Not stated. Countries: 1. Publications: 0.

ShareScore

28/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
8
Access
4
Reuse readiness
0
Engagement
4

Topics

Dataset details

Repository
ClinicalTrials.gov
Published
February 11, 2026
License
IPD-UNDECIDED
DOI
clinicaltrials.gov/NCT00570258

Scored with release 0.9.0

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.